556 results about "Gene vector" patented technology

The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.

A group of modular cloning vector plasmids for the synthesis of a transgene or other complicated DNA construct, by providing a backbone having docking points therein, for the purpose of gene expression or analysis of gene expression. The invention is useful for assembling a variety of DNA fragments into a de novo DNA construct or transgene by using cloning vectors optimized to reduce the amount of manipulation frequently needed. The module vector contains at least one multiple cloning site (MCS) and multiple sets of rare restriction and/or unique homing endonuclease (“HE”) sites, arranged in a linear pattern. This arrangement defines a modular architecture that allows the user to place domain modules or inserts into a PE3 transgene vector construct without disturbing the integrity of DNA elements already incorporated into the PE3 vector in previous cloning steps. The PE3 transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.

The invention discloses a CAR-T transgene vector based on replication defective recombinant lentivirus. The CAR-T transgene vector comprises an original nuclear replicon pUCOri sequence, a resistance gene AmpR sequence containing ampicillin, a virus replicon SV40 Ori sequence, a lentivirus packaging cis element, ZsGreen1 green fluorescent protein, an IRES ribosome binding sequence, a human EF1 alpha promoter , a chimeric antigen receptor of second-generation CAR or third-generation CAR and a regulating element, wherein the original nuclear replicon pUCOri sequence is used for plasmid replication; the resistance gene AmpR sequence is used for massively proliferating target strains; the virus replicon SV40 Ori sequence is used for enhancing replication in eukaryocyte; the lentivirus packaging cis element is used for lentivirus packaging; the ZsGreen1 green fluorescent protein is used for expressing green fluorescent for eukaryocyte; the IRES ribosome binding sequence is used for jointly transcribing and expressing protein; the human EF1 alpha promoter is used for conducting eukaryotic transcription on antigen receptor genes; the chimeric antigen receptor is used for forming the second-generation CAR or the third-generation CAR integrating recognition, transfer and start; the regulating element is used for enhancing expression efficiency of transgenes and used after eWPRE-enhanced type woodchuck hepatitis b virus is transcribed. Besides, the invention further discloses a construction method and application of the vector. By means of the CAR-T transgene vector and the construction method and application of the vector, secretion of cell factors and an in vitro killing effect of CAR-T cells can be remarkably improved, and the clinical treatment effect is remarkable.

The invention discloses construction and application of a CRISPR/Cas9 gene editing vector for microorganisms. The constructed CRISPR/Cas9 gene vector consists of a replication start site, a selection marker gene, a Cas9 protein gene, gRNA coding DNA, a homologous recombinant element and an operon. The CRISPR/Cas9 gene vector constructed by the invention is capable of editing (including performing such operations as knocking out, replacing, interpolating and the like on gene or DNA sequence) escherichia coli or corynebacterium glutamicum genome; and the gene vector has the advantages of being short in test cycle, time-saving and cost-saving, high in efficiency and the like.

The invention provides sgRNA and a gene vector for inhibiting bladder cancer by targeting human lncRNA-UCA1 and an application of the sgRNA; specifically, sgRNA sequences of an lncRNA-UCA1 gene and a PD-1 gene suitable for CRISPR-Cas9 targeted splicing are designed; by transforming plasmids of specific splicing lncRNA-UCA1 gene and CRISPR-Cas9 nuclease gene into human bladder cancer cells, the expression of the lncRNA-UCA1 gene drops so as to inhibit the growth of tumor cells; and the plasmid, together with a human PD-1 gene targeted knockout vector, is transformed into a humanized mouse model of bladder cancer transplanted tumor, so as to obviously inhibit the growth of tumors. According to the invention, the vector is simple in preparing steps, the sgRNA is good in targeting property and the CRISPR-Cas9 is high in knockout efficiency.

Methods and apparatus are provided for delivering drugs, gene vectors, naturally-occurring or synthetic hormones or proteins or other bioactive agents within a patient's vasculature. In a preferred embodiment, the apparatus comprises a material that elutes or secretes a bioactive agent and is held in place within the patient's vessel by an anchor. The material may comprise a biocompatible, and optionally, absorbable matrix, or a culture medium that sustains and nourishes stem cells, spleen cells or pancreatic islets or other beneficial cells. The anchor and material are sized and/or collapsible from a delivery configuration, in which the anchor and material may be delivered into the patient's vasculature within a delivery sheath, to a deployed configuration, wherein the anchor engages an interior wall of the patient's vessel. The apparatus of the invention may be temporarily or permanently implanted, and may in addition self reconfigure after a predetermined period of residency.

A novel nano polycation transgenic vector relates to a nano polycation transgenic vector of a cyclodextrin-polyethyleneimine-folacin ternary assembly structure which takes the cyclodextrin as a skeleton material and polymerizes the cyclodextrin after activated with small molecular polyethyleneimine(PEI) as well as couples the decorative folacin on the cyclodextrin-polyethyleneimine to manufacture the nano polycation transgenic vector with tumor targeting. The material composing method of the vector is simple and effective with a high recycling rate; the material is shown to have the characteristics of low poison and high transfecting efficiency by the filtering of a plurality of tumor cell strains and experiences in the body of a rat.

The invention discloses a boron-containing nano-mesoporous and macroporous bioactive glass, a preparation method thereof and the application thereof to medical supports. The boron-containing mesoporous bioactive glass is prepared by substituting BO33- for part of SiO44- by a sol-gel method. According to the method, controllable porosity (78 to 90 percent) is obtained by adjusting immersion times (2 to 5 times) and aperture (300 to 500 microns). The composite glass material has pores suitable for cell growth; tissue growth and nutrition transmission are facilitated due to the porosity characteristic; and the structural integrity of the supports can be maintained in vitro. When the boron content is 0 to 10 percent, the boron-containing ordered mesoporous bioactive glass support has large surface area of 365 to 194 m<2>/g and is suitable for serving as vectors of medicines and growth factors. The biological material can slowly release boron ions, can serve as a tissue repair material applied to bone and periodontium engineering, and can serve as vectors of medicines or genes.

The present invention provides novel multi-functional methacrylic copolymers that exhibit cationic pH-sensitive behavior as well as good water solubility under acidic conditions. The copolymers are constructed from tertiary amine methacrylates and poly(ethylene glycol) containing methacrylates. The copolymers are useful as gene vectors, pharmaceutical carriers, and in protein separation applications.

The invention discloses a nucleic acid transfected cationic liposome, a nucleic acid medicinal preparation comprising a cationic liposome as well as a preparation method and use thereof. The cationic liposome comprises a cationic liposome, an auxiliary liposome and a polyethylene glycol modified neutral liposome. The cationic liposome nucleic acid medicinal preparation comprises the cationic liposome and the nucleic acid medicinal preparation. The cationic liposome disclosed by the invention serves as a non-virus gene vector and is low in cytotoxicity, strong in blood stability and high in gene silencing efficiency. The highest gene silencing efficiency on a HepG-2 cell which constantly expresses luciferase is 90.8%. The cationic liposome has an excellent anti-non-specific protein adsorptive property and long recyclability, thus improving the stability and the running efficiency of the liposome and effectively improving the effect of the nucleic acid medicine. The cationic liposome nucleic acid medicinal preparation can be used in the field of medicine and the like.

The invention relates to PEI (Polyetherimide) modified chitosan triply compound gene vector coated with RGD (Arginyl-Glycyl-Aspartic acid)-chondroitin sulfate and a preparation method and application thereof. The triply compound gene vector is formed by mixing RGD polypeptide modified chondroitin sulfate, pDNA and PEI grafted chitosan in the mass ratio of 15:1:4. The transfection efficiency of a chitosan vector is improved by using a PEI grafting method; by using a coating method of electronegative chondroitin sulfate, red cells in blood plasma and plasma protein can be prevented from being adsorbed and reduced and the stability of blood circulation can be enhanced; in addition, by using the special targeted RGD polypeptide to modify the chondroitin sulfate, the transmembrane capability of compound particles can be enhanced. A triply gene delivery system can be constructed by taking the PEI grafted chitosan and DNA compound particles as the core and the RGD-modified chondroitin sulfate as the casing. The preparation method is simple and convenient and has mild conditions; the modified chitosan is used as a gene vector, so that the transfection efficiency is high and the cytotoxicity is low; in addition, the invention can effectively prevent the adsorption to the red cells and electronegative macromolecules, has favorable body fluid circulating stability and is hopeful to be used for gene treatment clinical experiments.

The invention provides a halogenohydrin dehalogenation enzyme originating from Agromyces sp., an encoding gene and a vector, and provides application of the halogenohydrin dehalogenation enzyme, the encoding gene and the vector in the process of preparing epoxy chloropropane and (R)-4- cyano-cn-3- hydroxybutyric acid ethyl ester. The halogenohydrin dehalogenation enzyme amino acid sequence is shown in SEQ ID NO.2, and the encoding gene sequence is shown in SEQ ID NO.1. The halogenohydrin dehalogenation enzyme, the encoding gene, the vector and the application have the advantages that the halogenohydrin dehalogenation enzyme originating from Agromyces sp. CCTCC NO. M 2012299 and the encoding gene of the halogenohydrin dehalogenation enzyme are provided; and the encoding gene of the halogenohydrin dehalogenation enzyme can be connected and constructed with an expression vector to obtain expression recombinant plasmid pET28b-Deh of the encoding gene, then can be transformed to escherichia coli BL21, obtained and transformed to escherichia coli bacterial strain respectively and correspondingly to obtain recombinant escherichia coli, and the recombinant escherichia coli has the halogenohydrin dehalogenation enzyme and can be utilized for carrying out biotransformation and catalysis for an enzyme source.

The invention belongs to the technical field of medicine, and relates to a guanidinylation SS-PAAs gene vector polymer as well as preparation and application thereof. The preparation method comprises the following steps: the guanidinylation SS-PAAs gene vector polymer is finally prepared from a cross-linking agent with a dual-acroloyl structure and a guanidinylation reagent through the processes of protection reaction performed on sulfonyl chlorides by sulfonyl chlorides, Michael addition polymerization and removal of protection of a benzene sulfonyl chloride guanidyl protecting agent in sequence. The polymer gene vector can be self-assembled with different kinds of gene segments to form a compound, so that the excellent biological membrane permeability is achieved, and the responsive degradation is realized in the reducible environment of cells, and the nuclear localization effect is achieved. The capability of loading the gene segments of the vector and the transport process can be regulated through controlling the guanidinylation reagent species, the proportion of the guanidinylation reagent in the polymer, and the molecular mass. The guanidinylation SS-PAAs gene vector can improve the transfection efficiency of genes, and reduce cytotoxicity, and is a novel gene vector adopted in the process of gene therapy.

The invention synthesizes a type of liver targeted, biodegradable high molecular MRI contrast medium with alpha,beta- poly [(2-aminoethyl) - L-asparagine] as fundamental chain, galactose as target gene, diethylenetriamine pentaacetic acid or L-tyrosine methyl ester derivatives as Gd3+ ligand. The contrast agent is less toxic, biocompatible, and has good relaxation rate than low molecular business contrast medium. Animal experiments showed that in liver organizations its enhancing effect is three times better than commercial and low molecular contrast medium (gadolinium sprayed acid cyelophosphate); the residence time in liver is more than 24 hours, which is 18 hours longer than low molecular business contrast medium. The feature is that Zeta potential for the contrast medium is negative and less than -10mV. We can achieve the MRI visible, the liver targeted, core-shell nanogene vector system with it as a gene vector system shell structure.